Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009046954> ?p ?o ?g. }
- W2009046954 endingPage "2925" @default.
- W2009046954 startingPage "2920" @default.
- W2009046954 abstract "This phase II study was undertaken to determine the efficacy of adding infusional fluorouracil (FU) to the chemotherapy doublet of gemcitabine and cisplatin in patients with advanced pancreatic cancer.The eligibility criteria included histologically or cytologically confirmed adenocarcinoma of the pancreas that was either unresectable or metastatic. No prior gemcitabine therapy was allowed. Patients received a combination of gemcitabine 1000 mg/m2 intravenously (IV) on days 1, 8, and 15; cisplatin 50 mg/m2 IV on days 1 and 15; and FU 175 mg/m2/d from days 1 to 15 by continuous IV infusion. Cycles were repeated every 28 days. Objective tumor response and toxicity were evaluated according to the World Health Organization criteria.A total of 47 patients (median age, 57 years; males, 59%) were enrolled. Sixteen patients had locally advanced (LA) disease, and 31 patients had metastatic disease. A total of 183 cycles of chemotherapy were administered. In patients with metastatic disease (n = 31), the probability of survival at 6 and 12 months was 66% and 34%, respectively. Objective partial response or stable disease was observed in 26% (90% confidence interval [CI], 0.14 to 0.41) and 61% (90% CI, 0.45 to 0.74) of patients, respectively. In patients with LA disease (n = 16), there were three partial responses (19%; 90 CI, 0.07 to 0.39). One patient in this group was successfully resected after FU-based radiotherapy. The most common grade 3 to 4 toxicities were neutropenia (60%), thrombocytopenia (42%), and anemia (26%). Thirteen patients were hospitalized for treatment-related complications.The combination of gemcitabine, cisplatin, and infusional FU has significant activity in patients with advanced pancreatic cancer." @default.
- W2009046954 created "2016-06-24" @default.
- W2009046954 creator A5000476372 @default.
- W2009046954 creator A5004764119 @default.
- W2009046954 creator A5011595369 @default.
- W2009046954 creator A5011817630 @default.
- W2009046954 creator A5021270199 @default.
- W2009046954 creator A5051921000 @default.
- W2009046954 creator A5069540576 @default.
- W2009046954 creator A5072203753 @default.
- W2009046954 creator A5073593424 @default.
- W2009046954 date "2003-08-01" @default.
- W2009046954 modified "2023-09-27" @default.
- W2009046954 title "Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer" @default.
- W2009046954 cites W1855374361 @default.
- W2009046954 cites W1931508686 @default.
- W2009046954 cites W1938837918 @default.
- W2009046954 cites W1959900711 @default.
- W2009046954 cites W1977264994 @default.
- W2009046954 cites W1981617190 @default.
- W2009046954 cites W1984254136 @default.
- W2009046954 cites W1995379798 @default.
- W2009046954 cites W2007349197 @default.
- W2009046954 cites W2021436384 @default.
- W2009046954 cites W2044573147 @default.
- W2009046954 cites W2081397749 @default.
- W2009046954 cites W2099015389 @default.
- W2009046954 cites W2100779962 @default.
- W2009046954 cites W2116538964 @default.
- W2009046954 cites W2123344367 @default.
- W2009046954 cites W2128889451 @default.
- W2009046954 cites W2135352785 @default.
- W2009046954 cites W2169278727 @default.
- W2009046954 cites W2285738680 @default.
- W2009046954 cites W2340730724 @default.
- W2009046954 cites W2396646859 @default.
- W2009046954 cites W4231089745 @default.
- W2009046954 cites W4237029509 @default.
- W2009046954 cites W4254119762 @default.
- W2009046954 cites W4297819854 @default.
- W2009046954 doi "https://doi.org/10.1200/jco.2003.03.022" @default.
- W2009046954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12885810" @default.
- W2009046954 hasPublicationYear "2003" @default.
- W2009046954 type Work @default.
- W2009046954 sameAs 2009046954 @default.
- W2009046954 citedByCount "46" @default.
- W2009046954 countsByYear W20090469542012 @default.
- W2009046954 countsByYear W20090469542013 @default.
- W2009046954 countsByYear W20090469542014 @default.
- W2009046954 countsByYear W20090469542015 @default.
- W2009046954 countsByYear W20090469542016 @default.
- W2009046954 countsByYear W20090469542018 @default.
- W2009046954 countsByYear W20090469542019 @default.
- W2009046954 crossrefType "journal-article" @default.
- W2009046954 hasAuthorship W2009046954A5000476372 @default.
- W2009046954 hasAuthorship W2009046954A5004764119 @default.
- W2009046954 hasAuthorship W2009046954A5011595369 @default.
- W2009046954 hasAuthorship W2009046954A5011817630 @default.
- W2009046954 hasAuthorship W2009046954A5021270199 @default.
- W2009046954 hasAuthorship W2009046954A5051921000 @default.
- W2009046954 hasAuthorship W2009046954A5069540576 @default.
- W2009046954 hasAuthorship W2009046954A5072203753 @default.
- W2009046954 hasAuthorship W2009046954A5073593424 @default.
- W2009046954 hasConcept C121608353 @default.
- W2009046954 hasConcept C126322002 @default.
- W2009046954 hasConcept C141071460 @default.
- W2009046954 hasConcept C2776694085 @default.
- W2009046954 hasConcept C2776737053 @default.
- W2009046954 hasConcept C2776907518 @default.
- W2009046954 hasConcept C2777063308 @default.
- W2009046954 hasConcept C2778239845 @default.
- W2009046954 hasConcept C2778248108 @default.
- W2009046954 hasConcept C2778764654 @default.
- W2009046954 hasConcept C2778822529 @default.
- W2009046954 hasConcept C2780210213 @default.
- W2009046954 hasConcept C2780258809 @default.
- W2009046954 hasConcept C2780456651 @default.
- W2009046954 hasConcept C2781182431 @default.
- W2009046954 hasConcept C31760486 @default.
- W2009046954 hasConcept C509974204 @default.
- W2009046954 hasConcept C71924100 @default.
- W2009046954 hasConcept C90924648 @default.
- W2009046954 hasConceptScore W2009046954C121608353 @default.
- W2009046954 hasConceptScore W2009046954C126322002 @default.
- W2009046954 hasConceptScore W2009046954C141071460 @default.
- W2009046954 hasConceptScore W2009046954C2776694085 @default.
- W2009046954 hasConceptScore W2009046954C2776737053 @default.
- W2009046954 hasConceptScore W2009046954C2776907518 @default.
- W2009046954 hasConceptScore W2009046954C2777063308 @default.
- W2009046954 hasConceptScore W2009046954C2778239845 @default.
- W2009046954 hasConceptScore W2009046954C2778248108 @default.
- W2009046954 hasConceptScore W2009046954C2778764654 @default.
- W2009046954 hasConceptScore W2009046954C2778822529 @default.
- W2009046954 hasConceptScore W2009046954C2780210213 @default.
- W2009046954 hasConceptScore W2009046954C2780258809 @default.
- W2009046954 hasConceptScore W2009046954C2780456651 @default.
- W2009046954 hasConceptScore W2009046954C2781182431 @default.
- W2009046954 hasConceptScore W2009046954C31760486 @default.